TY - JOUR
T1 - CT severity score
T2 - an imaging biomarker to estimate the severity of COVID-19 pneumonia in vaccinated and non-vaccinated population
AU - Gurumurthy, Balasubramanian
AU - Das, Sudha Kiran
AU - Shetty, Sachin
AU - Veerabhadrappa, Rakesh Chowkalli
AU - Kosinepalli, Sai Siddartha
AU - Dharamaraju, Swathi Hassan
N1 - Funding Information:
I sincerely thank our esteemed institution JSS Academy of Higher Education and Research, Mysore, for encouraging and providing support in all our endeavors. I also take this opportunity to express my gratitude to all the faculty, postgraduates, technical and supporting staff of Department of Radiology.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: In India, two vaccines received emergent use authorization, namely Covishield (a brand of the Oxford—Astra Zeneca vaccine manufactured by the Serum institute of India) and Covaxin (developed by Bharat Biotech) against COVID-19 disease. Chest CT is an objective way to assess the extent of pulmonary parenchymal involvement. This study aims to estimate the disease severity and outcome due to COVID-19 among vaccinated and non-vaccinated symptomatic patients and compare the same in Covishield versus Covaxin recipients using CT severity score. Results: A total of 306 patients were retrospectively evaluated. The mean age was 62.56 ± 8.9 years, and males [n-208 (67.97%)] were commonly affected. Of 306 patients, 143 were non-vaccinated (47%), 124 were partially vaccinated (40%), and 39 were completely vaccinated (13%). CT severity scores were reduced in both Covishield and Covaxin recipients in comparison with the non-vaccinated group [χ2 (2) = 16.32, p < 0.001]. There is a reduction in LOS among the vaccinated group, predominantly among the Covishield recipients. Conclusion: Vaccination confers protection from severe SARS-CoV2 infection and is associated with an overall reduction in mortality.
AB - Background: In India, two vaccines received emergent use authorization, namely Covishield (a brand of the Oxford—Astra Zeneca vaccine manufactured by the Serum institute of India) and Covaxin (developed by Bharat Biotech) against COVID-19 disease. Chest CT is an objective way to assess the extent of pulmonary parenchymal involvement. This study aims to estimate the disease severity and outcome due to COVID-19 among vaccinated and non-vaccinated symptomatic patients and compare the same in Covishield versus Covaxin recipients using CT severity score. Results: A total of 306 patients were retrospectively evaluated. The mean age was 62.56 ± 8.9 years, and males [n-208 (67.97%)] were commonly affected. Of 306 patients, 143 were non-vaccinated (47%), 124 were partially vaccinated (40%), and 39 were completely vaccinated (13%). CT severity scores were reduced in both Covishield and Covaxin recipients in comparison with the non-vaccinated group [χ2 (2) = 16.32, p < 0.001]. There is a reduction in LOS among the vaccinated group, predominantly among the Covishield recipients. Conclusion: Vaccination confers protection from severe SARS-CoV2 infection and is associated with an overall reduction in mortality.
UR - http://www.scopus.com/inward/record.url?scp=85128211637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128211637&partnerID=8YFLogxK
U2 - 10.1186/s43055-022-00768-2
DO - 10.1186/s43055-022-00768-2
M3 - Article
AN - SCOPUS:85128211637
SN - 0378-603X
VL - 53
JO - Egyptian Journal of Radiology and Nuclear Medicine
JF - Egyptian Journal of Radiology and Nuclear Medicine
IS - 1
M1 - 88
ER -
